Financing Development Stage Biotechnology Companies: Reverse Mergers vs. IPOs
Mark J. Ahn
Creighton University - College of Business Administration
Robert B. Couch
Willamette University - Atkinson Graduate School of Management; Willamette University (Atkinson GSM)
Willamette University (Atkinson GSM)
January 15, 2011
Midwest Finance Association 2012 Annual Meetings Paper
Journal of Health Care Finance, 38(1): 32-54, 2011
We examine reverse mergers (RMs) in the biotechnology industry and find that, when compared to initial public offerings (IPOs), RMs are smaller, have significantly lower market valuations relative to size, and generally invest less. We also find that RMs exhibit positive abnormal returns on the announcement date and throughout the first year after the RM event. In looking at liquidity measures, we find that RMs tend to be less liquid than IPOs and that illiquidity is greater during the six-month lock-up period following the RM event. Thus, RMs may be an appropriate alternative financing vehicle in capital intensive, high-risk biotechnology companies which require accessing deeper and larger pools of investors in public capital markets across multiple milestone periods in a 'pay for progress' environment.
Number of Pages in PDF File: 32
Keywords: biotechnology, reverse merger (RM), initial public offering (IPO)
JEL Classification: G14
Date posted: September 29, 2011 ; Last revised: November 22, 2014
© 2015 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo7 in 0.266 seconds